Medical Flowers Developments (MFD) is a biopharmaceutical company focused on the development of cannabinoid-based medicines, with a strictly pharmacological approach. We operate at the intersection of biotechnology, advanced formulation and clinical development, oriented toward regulated programs and collaboration with the pharmaceutical industry.
MFD collaborates with a network of specialized industrial and scientific partners, including Phytoplant Research, Cafosa Gum and the Faculty of Pharmacy of the University of Barcelona (SDM-UB). These collaborations constitute the technical and industrial foundation of the project, integrating capabilities in raw materials, formulation, manufacturing and pharmaceutical quality control. On this basis, the model is designed to incorporate new industrial, pharmaceutical and clinical partners interested in participating in the development and validation of cannabinoid-based pharmaceutical programs under regulated standards.
Development is conceived from the earliest stages under criteria of quality, reproducibility and regulatory compliance, aligned with the European regulatory framework and with the principles of the European Pharmacopoeia (Ph. Eur.). The early clinical program is designed as a tool for evidence generation, regulatory risk reduction and the enablement of future pharmaceutical development strategies.
Medical Flowers Developments collaborates with pharmaceutical and biotech companies interested in cannabinoid clinical trials. The company maintains an open approach to professional discussions focused on development, innovation, and investment in regulated projects.
